Short answer
ANAPTYSBIO, INC (ANAB) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $30M (down 60.3% year over year) with net income of $4M.
Q3 2026 key financials · XBRL
- Revenue
- $30M
- −60.3% YoY
- Net income
- $4M
- −74.4% YoY
- Operating margin
- 65.7%
- EPS (diluted)
- $0.11
- −76.1% YoY
Source: XBRL data from the ANAPTYSBIO, INC (ANAB) Q3 2026 10-Q on SEC EDGAR. USD.
ANAPTYSBIO, INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $30.3M, down $46.0M YoY from $76.3M, primarily reflecting no milestone revenue versus $50.0M
- Best performer, Jemperli royalties $29.6M, up $4.7M from $24.9M; worst, GSK milestone revenue $0 vs $50.0M
- Continuing operations net income $3.9M; non-cash royalty interest expense $18.7M vs $22.5M YoY
- Cash, cash equivalents and investments $153.0M, down from $164.1M at June 30; operating cash flow $(9.5)M vs $4.8M
- Capital deployment: $5.9M royalty-liability repayments and $4.4M stock issuance proceeds; funding expected for at least twelve months
Risk Factors
- Newly added operational risk: April 2026 Spin-Off split management attention between two public companies
- Most material legal risk: Tesaro litigation trial held July 14-17, 2026, with potential loss of dostarlimab rights
- Regulatory risk: U.S. tariffs on pharmaceutical ingredients, including China-sourced inputs, may increase Jemperli costs
- Near-term market risk: Keytruda competition and future biosimilars could reduce Jemperli royalties
- Financial risk: Federal NOL utilization limited to $6.4 million annually under Section 382
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANAPTYSBIO, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.